FGFR2 and cholangiocarcinoma: Lirafugratinib is a highly FGFR2-selective inhibitor engineered to spare other FGFR paralogs and retain potency against prevalent resistance mutations, with early clinical responses in FGFR2-altered cholangiocarcinoma, including in patients previously exposed to FGFR inhibitors.18